Sanofi - Company Profile
Powered by
All the data and insights you need on Sanofi in one report.
- Save hours of research time and resources with
our up-to-date Sanofi Strategy Report
- Understand Sanofi position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreSanofi is a healthcare company, which is engaged in the discovery, development, manufacturing, and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, rare diseases, multiple sclerosis; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals, and supplements. Sanofi's R&D efforts focus on advancing a combination drug to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa, and the Middle East. Sanofi is headquartered in Paris, Ile-de-France, France.
Sanofi premium industry data and analytics
Products and Services
Products | Brands |
---|---|
- | Dupixent |
Specialty Care: | Aubagio |
Atopic Dermatitis | Lemtrada |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In May, the company signed a US$1.2 billion licensing deal with Novavax for the COVID-19 vaccine. |
2024 | Contracts/Agreements | In May, the company signed an agreement with Sartorius to create an integrated and continuous biomanufacturing platform. |
2024 | Plans/Strategy | In May, the company announced its plans to invest more than EUR1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhone) in France. |
Competitor Comparison
Key Parameters | Sanofi | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
---|---|---|---|---|---|
Headquarters | France | United States of America | Switzerland | United States of America | United States of America |
City | Paris | New Brunswick | Basel | Rahway | New York |
State/Province | Ile-de-France | New Jersey | - | New Jersey | New York |
No. of Employees | 87,994 | 131,900 | 103,605 | 72,000 | 88,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Paul Hudson | Chief Executive Officer; Director | Executive Board | 2019 | 55 |
Francois-Xavier Roger | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | - |
Natalie Bickford | Chief People Officer; Executive Vice President | Senior Management | 2020 | 53 |
Emmanuel Frenehard | Chief Digital Officer | Senior Management | 2023 | - |
Frederic Oudea | Chairman | Non Executive Board | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer